CGON vs. BEAM, NVAX, KYMR, RXRX, ADMA, FUSN, SANA, INBX, VCEL, and TWST
Should you be buying CG Oncology stock or one of its competitors? The main competitors of CG Oncology include Beam Therapeutics (BEAM), Novavax (NVAX), Kymera Therapeutics (KYMR), Recursion Pharmaceuticals (RXRX), ADMA Biologics (ADMA), Fusion Pharmaceuticals (FUSN), Sana Biotechnology (SANA), Inhibrx (INBX), Vericel (VCEL), and Twist Bioscience (TWST). These companies are all part of the "biological products, except diagnostic" industry.
Beam Therapeutics (NASDAQ:BEAM) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.
In the previous week, CG Oncology had 4 more articles in the media than Beam Therapeutics. MarketBeat recorded 8 mentions for CG Oncology and 4 mentions for Beam Therapeutics. CG Oncology's average media sentiment score of 0.84 beat Beam Therapeutics' score of 0.41 indicating that Beam Therapeutics is being referred to more favorably in the media.
99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 4.2% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Beam Therapeutics currently has a consensus price target of $40.18, indicating a potential upside of 68.48%. CG Oncology has a consensus price target of $63.75, indicating a potential upside of 87.78%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CG Oncology is more favorable than Beam Therapeutics.
Beam Therapeutics received 32 more outperform votes than CG Oncology when rated by MarketBeat users. However, 81.82% of users gave CG Oncology an outperform vote while only 51.25% of users gave Beam Therapeutics an outperform vote.
CG Oncology has a net margin of 0.00% compared to CG Oncology's net margin of -37.33%. Beam Therapeutics' return on equity of 0.00% beat CG Oncology's return on equity.
CG Oncology has lower revenue, but higher earnings than Beam Therapeutics.
Summary
CG Oncology beats Beam Therapeutics on 9 of the 15 factors compared between the two stocks.
Get CG Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CG Oncology Competitors List
Related Companies and Tools
